industry intelligence Measured conclusion Latest qualified tape

Industry Sentiment Dossier

Drug Manufacturers - Specialty & Generic sentiment intelligence

Company-news tone, narrative breadth, confidence, catalyst concentration and market confirmation examined as separate evidence layers.

Constructive but selective 55/100 narrative breadth 70/100 evidence confidence 400 qualified equities from 648 latest records
Peer rank82 of 157weighted group score
Qualified coverage62%248 records withheld
Direct evidence100%5866 company matches
Story dispersion4.2cross-company score spread
Relative to context-0.1versus Healthcare
Latest refresh12 Aug 20263003 publisher signals

Executive Evidence Brief

A balanced headline masks a selective company tape

Aggregate tone remains near neutral, so breadth, catalysts and company-level outliers carry more information than the headline score alone.

Directional score52.6weighted polarity, separate from reliability
Breadth55constructive minus cautious participation
Confidence70depth, directness, freshness and agreement

Evidence that supports the read

Constructive participation reaches 55/100 across qualified company reads.

Evidence confidence is 70/100 across 400 qualified equities.

Direct company coverage supplies 100% of the measured article set.

Positive one-week price responses appear across 56% of measured equities.

Conditions that limit conviction

No material evidence constraint is currently dominant.

Narrative Breadth

How widely tone is shared

400 equities
55Breadth
Constructive4411.0%
Balanced35288.0%
Cautious41.0%

Score Distribution

Shape of the company tape

Neutral range 43 to 57
0Strong caution
4Cautious
352Balanced
42Constructive
2Strongly constructive

Evidence Quality

Reliability of the read

Confidence is not polarity
70/100 group confidence
High confidence194
Usable evidence70
Developing136

5885 relevant story observations across 3003 publisher signals. 100% is direct company evidence.

13-Week Trajectory

Weighted tone and participation

Completed observations only
15 Jun: tone 51.7, breadth 51.4, 175 observations22 Jun: tone 52.2, breadth 52.9, 171 observations29 Jun: tone 52.4, breadth 53.4, 178 observations06 Jul: tone 52.4, breadth 53.7, 175 observations13 Jul: tone 52.3, breadth 52.8, 176 observations20 Jul: tone 52.4, breadth 55.1, 178 observations27 Jul: tone 52.3, breadth 53.9, 180 observations03 Aug: tone 53.1, breadth 55.6, 152 observations10 Aug: tone 53.1, breadth 60.1, 74 observations 100500
18 May29 Jun10 Aug
Weighted toneNarrative breadthNeutral 50

The path uses a fixed quality sample of up to 180 current constituents to keep the historical query reproducible. Earlier observations are not rewritten by later headlines.

Market Confirmation

How price is responding to the news tape

400 securities measured

Price response is a diagnostic cross-check. It does not alter the sentiment score, so agreement and disagreement remain visible.

Confirmed by price164% of qualified equities
News-price disagreement14737% of qualified equities
Cautious news absorbed20% of qualified equities
No decisive price test23559% of qualified equities
Median 1W return+0.60%
Median 4W return-0.55%
Positive 1W response56%
Active trend signal34%
Above Fair Value46%
Median Fair Value gap-2.90%

Internal Leadership

Country map

15 qualified groups

15 thin groups are withheld because they contain fewer than 5 qualified securities.

Peer Comparison

Where this read sits in the ranked tape

Rank 82 of 157

Catalyst Lens

What is moving the narrative

Latest company observations
Market update26065.0% of equities · tone 52.0
Earnings12431.0% of equities · tone 53.9
Deals and strategy61.5% of equities · tone 52.1
Capital return41.0% of equities · tone 54.8
Guidance20.5% of equities · tone 48.0
Analyst action20.5% of equities · tone 51.0
Regulatory and legal20.5% of equities · tone 50.0

Publisher Lens

Where the latest observations came from

Not an independence count
TradingView10426.0% of equities · tone 50.7
scanx.trade379.2% of equities · tone 52.7
simplywall.st369.0% of equities · tone 54.0
TipRanks235.8% of equities · tone 52.5
MarketBeat194.8% of equities · tone 54.9
TradingKey194.8% of equities · tone 51.6
Kalkine Media112.8% of equities · tone 53.2
Market source102.5% of equities · tone 51.9

Positioning Lens

What deserves attention

Score rank#82among 157 measured industries
Parent spread-0.1versus Healthcare
Cross-company dispersion4.2higher values mean a less uniform tape

Security Evidence

The equities behind the read

Open any ticker for its complete dossier

Constructive leaders

Tsumura & Co.

Balanced read · +0.5% 1W

Earnings · 24/100 confidence · 2 direct stories
Canopy Growth Corporation

News confirmed by price · +1.6% 1W

Market update · 75/100 confidence · 22 direct stories
Laurus Labs Limited

News confirmed by price · +1.5% 1W

Earnings · 72/100 confidence · 7 direct stories
Avant Brands Inc.

Balanced read · +0.0% 1W

Earnings · 79/100 confidence · 11 direct stories
Vaishali Pharma Limited

Positive news being faded · -1.0% 1W

Market update · 75/100 confidence · 23 direct stories
EMCURE PHARMACEUTICALS L

Balanced read · +0.9% 1W

Earnings · 64/100 confidence · 4 direct stories
Liquidia Technologies Inc

News confirmed by price · +7.3% 1W

Earnings · 91/100 confidence · 27 direct stories
PBH62
Prestige Brand Holdings Inc

News confirmed by price · +9.2% 1W

Earnings · 90/100 confidence · 29 direct stories

Cautious laggards

RGC39
Regencell Bioscience Holdings Ltd

Caution confirmed by price · -12.5% 1W

Market update · 71/100 confidence · 18 direct stories
Hims Hers Health Inc

Bad news being absorbed · +13.8% 1W

Market update · 88/100 confidence · 34 direct stories
Klaria Pharma Holding AB (publ.)

Bad news being absorbed · +11.3% 1W

Guidance · 51/100 confidence · 3 direct stories
Zoetis Inc.

Caution confirmed by price · -1.6% 1W

Earnings · 49/100 confidence · 2 direct stories
Zoetis Inc.

Price moving ahead of tone · -6.2% 1W

Earnings · 67/100 confidence · 4 direct stories
ZIM Laboratories Limited

Balanced read · -0.9% 1W

Earnings · 47/100 confidence · 2 direct stories
Turk Ilac Ve Serum Sanayi Anonim Sirketi

Balanced read · -3.2% 1W

Market update · 45/100 confidence · 2 direct stories
RDY44
Dr. Reddy’s Laboratories Ltd ADR

Balanced read · +0.5% 1W

Market update · 75/100 confidence · 51 direct stories

Attention leaders

ACB57
Aurora Cannabis Inc

Price moving ahead of tone · +4.5% 1W

Market update · 75/100 confidence · 60 direct stories
Alkermes Plc

Price moving ahead of tone · -7.4% 1W

Earnings · 75/100 confidence · 60 direct stories
TAK56
Takeda Pharmaceutical Co Ltd ADR

Balanced read · -0.9% 1W

Market update · 75/100 confidence · 60 direct stories
Incannex Healthcare Ltd ADR

Price moving ahead of tone · -6.9% 1W

Market update · 75/100 confidence · 60 direct stories
Amneal Pharmaceuticals, Inc. Class A Common Stock

Balanced read · +2.2% 1W

Market update · 76/100 confidence · 59 direct stories
Tilray Inc

Price moving ahead of tone · +17.0% 1W

Market update · 75/100 confidence · 58 direct stories
Cronos Group Inc

Balanced read · +0.7% 1W

Market update · 75/100 confidence · 57 direct stories
HLN58
Haleon plc

Balanced read · +0.9% 1W

Market update · 75/100 confidence · 57 direct stories

Latest Evidence Ledger

Recent company-level observations

18 displayed

Regeneron, Tenet leads top healthcare companies with highest earnings beats (XLV:NYSEARCA)

Seeking Alpha · Earnings · Balanced read

71/100 confidence · 100% direct evidence

Short Interest in Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Decreases By 84.4%

MarketBeat · Market update · Positive news being faded

75/100 confidence · 100% direct evidence

Takeda Pharmaceutical (TSE:4502) Is Using AI To Advance Three Late Stage Medicines

simplywall.st · Market update · Balanced read

73/100 confidence · 100% direct evidence

Teva (TEVA) Is Up 6.0% After Moody’s Upgrade To Investment Grade And Higher 2026 Guidance

simplywall.st · Earnings · News confirmed by price

90/100 confidence · 100% direct evidence

Teva (TEVA) Is Up 6.0% After Moody’s Upgrade To Investment Grade And Higher 2026 Guidance

simplywall.st · Market update · Positive news being faded

80/100 confidence · 100% direct evidence

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call

StockStory · Earnings · Balanced read

60/100 confidence · 100% direct evidence

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Market source · Earnings · Price moving ahead of tone

89/100 confidence · 100% direct evidence
ZTS49

Citigroup Lowers Zoetis (NYSE:ZTS) Price Target to $96.00

MarketBeat · Market update · Price moving ahead of tone

86/100 confidence · 100% direct evidence
ACB52

Update: Curaleaf Proposing to Acquire Aurora Cannabis For $4.00 Per Share

Market source · Market update · Price moving ahead of tone

93/100 confidence · 100% direct evidence

Hims & Hers Health (NYSE:HIMS) Price Target Cut to $33.00 by Analysts at Citigroup

MarketBeat · Market update · Price moving ahead of tone

92/100 confidence · 100% direct evidence

Why Avant Brands Inc stock is skyrocketing today

Wealth Awesome · Earnings · Balanced read

79/100 confidence · 100% direct evidence

Zhejiang Hisun Stock Soars 8.62%, Hits Intraday High of CNY 14.42

MarketsMojo · Market update · Price moving ahead of tone

55/100 confidence · 100% direct evidence

PYFA's Probiotec Achieves Green Star 6-Star Rating, Reinforcing ESG Commitment in Sustainable Building

openPR.com · Analyst action · Balanced read

47/100 confidence · 100% direct evidence

Buy Gland Pharma; target of Rs 3080: Motilal Oswal

Moneycontrol.com · Market update · Balanced read

93/100 confidence · 100% direct evidence
HIK55

Berenberg Bank Forecasts Strong Price Appreciation for Hikma Pharmaceuticals (LON:HIK) Stock

MarketBeat · Market update · Price moving ahead of tone

84/100 confidence · 100% direct evidence
HLN61

Royal Bank Of Canada Issues Positive Forecast for Haleon (LON:HLN) Stock Price

MarketBeat · Market update · News confirmed by price

68/100 confidence · 100% direct evidence

Abbott India shares climb over 2% to Rs 28,120.00

Moneycontrol.com · Market update · Balanced read

63/100 confidence · 100% direct evidence

Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News

Market source · Earnings · Price moving ahead of tone

86/100 confidence · 100% direct evidence

Reproducible Method

How to read this dossier

Direction

The score measures the polarity of qualified published news after relevance, source quality, event importance and freshness weighting. It is centred at 50.

Breadth

Breadth measures how widely constructive or cautious classifications are shared. A few extreme equities cannot create broad participation.

Confidence

Confidence measures sample depth, direct-company coverage, publisher diversity, freshness and agreement. It is intentionally separate from direction.

Market confirmation

Completed weekly price data tests whether the market confirms, rejects or absorbs the narrative. Price never feeds back into the sentiment score.

Coverage controls

Unqualified ticker records are excluded, and subgroup maps require at least five qualified securities. Thin slices are disclosed instead of ranked.

Interpretation

This is a current evidence classification, not a forecast, target, recommendation or measure of investor positioning.

Evidence context